PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 153 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $20,469,869 | +34.8% | 590,761 | +12.5% | 0.00% | 0.0% |
| Q1 2024 | $15,189,407 | +28.6% | 525,040 | +1.9% | 0.00% | +50.0% |
| Q4 2023 | $11,813,994 | +51.6% | 515,220 | +10.3% | 0.00% | 0.0% |
| Q3 2023 | $7,792,946 | -49.5% | 467,203 | -16.5% | 0.00% | -33.3% |
| Q2 2023 | $15,445,380 | +46.2% | 559,210 | +21.7% | 0.00% | +50.0% |
| Q1 2023 | $10,567,350 | +57.1% | 459,450 | -25.5% | 0.00% | 0.0% |
| Q4 2022 | $6,728,459 | +105328.7% | 616,724 | -18.5% | 0.00% | 0.0% |
| Q3 2022 | $6,382 | +27.7% | 757,079 | +19.8% | 0.00% | +100.0% |
| Q2 2022 | $4,999 | -99.9% | 631,916 | +82.4% | 0.00% | -50.0% |
| Q1 2022 | $8,201,000 | +94.0% | 346,359 | +180.2% | 0.00% | +100.0% |
| Q4 2021 | $4,228,000 | -43.6% | 123,629 | -70.8% | 0.00% | -50.0% |
| Q3 2021 | $7,499,000 | -57.4% | 423,195 | +8.0% | 0.00% | -50.0% |
| Q2 2021 | $17,590,000 | +64.0% | 391,943 | -5.4% | 0.00% | +33.3% |
| Q1 2021 | $10,727,000 | -3.6% | 414,134 | -24.9% | 0.00% | 0.0% |
| Q4 2020 | $11,124,000 | +156.2% | 551,787 | +148.5% | 0.00% | +200.0% |
| Q3 2020 | $4,342,000 | -53.6% | 222,080 | -58.1% | 0.00% | -66.7% |
| Q2 2020 | $9,361,000 | +1984.9% | 530,048 | +732.1% | 0.00% | – |
| Q1 2020 | $449,000 | +216.2% | 63,701 | +216.3% | 0.00% | – |
| Q4 2019 | $142,000 | -92.5% | 20,139 | -87.2% | 0.00% | -100.0% |
| Q3 2019 | $1,885,000 | +547.8% | 156,961 | +552.3% | 0.00% | – |
| Q2 2019 | $291,000 | -77.1% | 24,061 | -76.2% | 0.00% | – |
| Q1 2019 | $1,269,000 | +575.0% | 100,992 | +260.7% | 0.00% | – |
| Q4 2018 | $188,000 | -53.6% | 27,999 | -28.9% | 0.00% | – |
| Q3 2018 | $405,000 | -27.3% | 39,369 | -52.5% | 0.00% | – |
| Q2 2018 | $557,000 | +108.6% | 82,864 | +166.7% | 0.00% | – |
| Q1 2018 | $267,000 | -56.6% | 31,069 | +5.1% | 0.00% | – |
| Q4 2017 | $615,000 | +118.1% | 29,563 | +121.6% | 0.00% | – |
| Q3 2016 | $282,000 | – | 13,340 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |